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Abstract The prevalence of HIV-associated neurocognitive
disorders (HAND) remains high in patients with effective
suppression of virus replication by combination antiretroviral
therapy (cART). Several neurotransmitter systems were re-
ported to be abnormal in HIV-infected patients, including the
inhibitory GABAergic system, which mediates fine-tuning of
neuronal processing and plays an essential role in cognitive
functioning. To elucidate the role of abnormal GABAergic
transmission in HAND, the expression of GABAergic
markers was measured in 449 human brain specimens from
HIV-infected patients with and without HAND. Using real-
time polymerase chain reaction, immunoblotting and immu-
nohistochemistry we found that the GABAergic markers were
significantly decreased in most sectors of cerebral neocortex,
the neostriatum, and the cerebellum of HIV-infected subjects.
Low GABAergic expression in frontal neocortex was corre-
lated significantly with high expression of endothelial cell
markers, dopamine receptor type 2 (DRD2L), and
preproenkephalin (PENK) mRNAs, and with worse perfor-
mance on tasks of verbal fluency. Significant associations
were not found between low GABAergic mRNAs and HIV-
1 RNA concentration in the brain, the history of cART, or HIV
encephalitis. Pathological evidence of neurodegeneration of
the affected GABAergic neurons was not present. We con-
clude that abnormally low expression of GABAergic markers
is prevalent in HIV-1 infected patients. Interrelationships with
other neurotransmitter systems including dopaminergic trans-
mission and with endothelial cell markers lend added support
to suggestions that synaptic plasticity and cerebrovascular
anomalies are involved with HAND in virally suppressed
patients.
Keywords Autopsy . Glutamate decarboxylase . GABA .
GABAergic . HIVassociated neurocognitive disorders . HIV
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Introduction
The prevalence of HIV-associated neurocognitive disorders
(HAND) is substantial in patients treated with cART
(McArthur et al. 2010). HAND was linked to the neuropath-
ological changes produced byHIVencephalitis (HIVE) before
the era of cART (Budka 1991). Data from the cART era,
however, are far less supportive of the putative association
between HAND and HIVE (Gelman 2015). While the fre-
quency of HIVE declined in cART-treated patient cohorts to
below 5 %, the prevalence of HAND remains as high as 50 %
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(McArthur et al. 2010). Neurovirological and brain gene ex-
pression data both show that the overwhelming majority of
patients with HAND taking cART do not have HIVE, and
they are not likely to harbor a high concentration of replicating
HIV in the CNS (Gelman et al. 2012a, 2013). Thus, the path-
ophysiology of HAND remains poorly understood, especially
when virus replication is suppressed with cART.
HIVE is associated with synaptodendritic simplification
and neuronal loss in the later stages of infection (Masliah et
al. 1997). Concentrations of several synaptic structural pro-
teins are abnormal and local protein turnover in synapses may
be abnormal in HIVE (Nguyen et al. 2010; Gelman and
Nguyen 2010). Those aspects of the neuropathology imply
that cART-treated patients might harbor subtle types of dys-
function in synaptic transmission due to synaptic plasticity, or
functional changes that are not driven by morphological
changes or neurodegeneration (Gelman et al. 2004, 2012b).
There is neurochemical evidence that GABAergic (Koutsilieri
et al. 2001; Gelman et al. 2012b), dopaminergic (Nath et al.
2000; Koutsilieri et al. 2001; Gelman et al. 2006; Gelman et
al. 2012a, 2012b), cholinergic (Koutsilieri et al. 2001), gluta-
matergic (Ernst et al. 2010) and serotonergic (Murray 2003)
neurotransmitter systems are perturbed in these patients.
Decreased immunostaining of GABAergic neocortical neu-
rons in HIVE is especially well-documented (Masliah et al.
1992, 1995; Fox et al. 1997). GABAergic markers including
calbindin and somatostatin exhibit decreased immunostaining
in tissue sections with HIVE (Masliah et al. 1992, 1995; Fox
et al. 1997), and potential synergy between HAND and con-
comitant methamphetamine abuse has been suggested for
these outcomes (Langford et al. 2003; Chana et al. 2006).
Other evidence shows that several mRNA transcripts
pertaining to GABAergic proteins are dysregulated in the dor-
solateral prefrontal cortex (DLPFC) of HIVE patients
(Gelman et al. 2004, 2012a). Whether disturbances in neural
transmission in HIV infection represent synaptic plasticity
among viable synaptic networks, versus outright neuronal
death and subsequent degeneration remains controversial.
Inhibitory GABAergic interneurons constitute 20 % of the
total number of neurons in the neocortex. These neurons mod-
ulate the activity of principal cells via alteration of the syn-
chronization of excitatory activity of pyramidal neurons, and
this is associated with cognitive and behavioral functions
(Markram et al. 2004). Abnormal GABAergic neural trans-
mission is present in brain specimens from patients with epi-
lepsy, major depressive disorders and schizophrenia (Prince
and Wilder 1967; Sanacora and Saricicek 2007; Hashimoto et
al. 2008). Neurocognitive impairment in these diseases is driv-
en in part by abnormal output of the DLPFC, and can lead to
worse performance on tasks of abstract/executive function and
verbal fluency (Volk et al. 2000; Thompson et al. 2009). The
same underlying neuropsychological disorders often occur in
patients with HAND (Klinkenberg et al. 2004; Iudicello et al.
2007) and could worsen and/or contribute to dysfunction of
the DLPFC in patients with HAND (Woods et al. 2009).
In addition to modulating neocortical output, GABAergic
interneurons play a pivotal role in neurovascular coupling, in
which neurotransmitters regulate local microvascular blood
flow in the neurovascular unit (Fergus and Lee 1997;
Kocharyan et al. 2008). Using blood oxygen dependent con-
trast imaging (BOLD), several diseases exhibit disturbed reg-
ulation of cerebral blood flow, which often is linked to chang-
es in GABAergic transmission (Northoff et al. 2007). Cerebral
blood flow assessed using BOLD also is abnormal in HIV
infected patients with and without HAND; the mechanism is
not known and a potential role for altered GABAergic trans-
mission has not been examined heretofore (Ances et al. 2011;
Towgood et al. 2012). Thus, altered cerebral blood flowmight
be involved in HAND and HIV-associated changes in
neurovascular coupling.
GABAergic neurons synthesize GABA via a rate-limiting
reaction that is catalyzed by two glutamic acid decarboxylase
(GAD) enzymes (GAD67 and GAD65, respectively). These
two proteins are encoded by independently regulated genes
located on chromosomes 2 and 10 (GAD1 and GAD2, respec-
tively). Both proteins are useful histological markers of
GABAergic interneurons, although they exhibit unique pat-
terns of cellular expression (Soghomonian and Martin 1998).
Another marker of GABAergic interneurons is the gap junc-
tion protein connexin 36 (encoded by GJD2mRNA) (Hestrin
and Galarreta 2005). Dendrites of GABAergic interneurons
are interconnected by connexin 36 gap junctions and form
complex inhibitory neural networks that provide critical mod-
ulation of frontal lobe output (Bennett and Zukin 2004;
Hestrin and Galarreta 2005). Disrupting GJD2 expression
produces a loss of electrical coupling among GABAergic in-
terneurons and leads to ineffective generation of fast synchro-
nized oscillations in neocortical neural networks (Bennett and
Zukin 2004). Clinically, the loss of GABAergic control of fast
and ultrafast rhythms can produce abnormalities in neuronal
processing, sensory perception, motor performance, learning,
attention, and memory consolidation in brain neocortex
(Bennett and Zukin 2004).
In order to better understand abnormal GABAergic trans-
mission in HIV infected patients several issues need to be
elucidated: 1) It is not known whether replicating HIV in the
brain drives GABAergic changes, or whether suppressing vi-
rus replication with cART normalizes the change; 2) Although
HAND without HIVE is the dominant clinicopathological se-
quence in virally suppressed patients (Gelman et al. 2012a;
Gelman 2015), the importance of GABAergic anomalies in
these patients and the role of HIVE need to be elucidated; 3) It
is not clear what type of neuropsychological dysfunction, if
any, is associated with GABAergic changes in HAND. 4) It
remains unclear whether loss of GABAergic marker protein
represents the death of inhibitory neurons (i.e., classical
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pathological neurodegeneration) as is often suggested, or in-
stead reflects modified expression of GABAergic marker pro-
teins in viable interneurons (i.e., accommodation due to syn-
aptic plasticity) (Akbarian et al. 1995; Volk et al. 2000;
Gelman et al. 2006). 5) Basic brain regional anatomy and
circuit-level dysfunction of GABAergic inhibitory networks
need to be better characterized in HIV infected subjects
(Gelman et al. 2012a). 6) Because of the role of GABA in
regulating cerebral blood flow, it is not known whether
GABAergic anomalies contribute to abnormal neurovascular
biology in HIV infected patients (Strazza et al. 2011). To ad-
dress these issues we evaluated neurochemical markers of
GABAergic transmission in 449 brain specimens obtained




GABAergic mRNA concentrations were measured in the dor-
solateral prefrontal cortex (DLPFC) of 515 human post-
mortem brain specimens obtained from National
NeuroAIDS Tissue consortium (NNTC) (Morgello et al.
2001). This particular patient cohort was described in a previ-
ous communication (Gelman et al. 2012b). DLPFC is of prime
relevance because the functional output of this brain sector is
abnormal in HAND (Woods et al. 2009). 449 of the patients
were infected with HIV-1 and 66 were demographically com-
parable HIV seronegative decedents (Gelman et al. 2006,
2012b) (Table S1). 131 out of 449 of the HIV-infected patients
died before 1997 and/or before cART was introduced to the
patient. cART status was defined as being active if the patient
had taken at least 2 nucleoside/nucleotide reverse transcriptase
inhibitors (NRTIs) or 1 nonnucleoside reverse transcriptase
inhibitor (NNRTI) and 1 protease inhibitor within 1 year of
death (Gelman et al. 2013). 290 out of 313 patients with doc-
umented cART status were cART active within 1 year of
death. 219 out of 449 of the HIV-infected patients participated
in longitudinal clinical studies after 1999 during the cARTera,
which included neuropsychological testing in the 6 months
before death. For the subjects who were studied clinically,
written consent was obtained for subjects at four collection
sites in the USA. The following offices maintained institution-
al review boards (IRBs) that provided oversight for the pro-
tection of human subjects: 1) The University of TexasMedical
Branch Office of Research Subject Protections; 2) Mount
Sinai Medical Center Program for the Protection of Human
Subjects; 3) University of California, San Diego Human
Research Protections Program; 4) University of California,
Los Angeles Office of the Human Research Protection
Program.
Neuropsychological Testing and Substance use Survey
Neuropsychological evaluations and substance use surveys
were performed every 6 months using the protocol of the
National NeuroAIDS Tissue Network (NNTC). The NNTC
neurocognitive test battery included assessment of seven cog-
nitive domains: 1) verbal fluency (Controlled Oral Word
Association Test, COWAT- FAS); 2) speed of information
processing (Wechsler adult intelligence scale, WAIS-III Digit
Symbol and Symbol Search subtest and Trail Making Test
Part A); 3) learning (Hopkins Verbal Learning Test –
Revised, HVLT–R; Total Trial 1–3 Recall and Brief
Visuospatial Memory Test – Revised, BVMT–R, Total Trial
1–3 Recall); 4) memory (HVLT–RDelayed Recall, BVMT–R
Delayed Recall); 5) executive functions (Wisconsin Card
Sorting Test, WCST 64-item version; perseverative responses
and TMT Part B) (6) attention and work- ing memory (WAIS-
III Letter-Number Sequencing, PASAT-50); 7) motor
(Grooved Pegboard Test, dominant and nondominant hand
performances). The Wide Range Achievement Test-3
(WRAT-3) Reading subtest was administered as an estimate
of premorbid verbal intellectual functioning (Woods et al.
2004). The Psychiatric Research Interview for Substance
and Mental Disorders (PRISM) or the Composite
International Diagnostic Interview (CIDI) was used to obtain
self-reported lifetime histories of substance abuse and depen-
dence (Robins et al. 1988; Morgello et al. 2001). A diagnosis
of HAND was assigned guided by American Academy of
Neurology criteria as modified by the Frascati Criteria.
Brain Specimen Dissection and Neuropathological Data
Brain specimens obtained fresh at autopsy were bisected in
the sagittal plane. One hemisphere was sliced fresh and the
slices were stored at – 80 °C. The other hemisphere was
immersed in a 20 % formalin solution at 4 °C for 10 days.
200–300 mg of frozen grey matter from the dorsolateral
prefrontal cortex in Brodmann area 9 or 8 was dissected
for mRNA and protein extraction. Other brain regions were
dissected for regional comparisons as indicated in the fig-
ures and tables. Frozen samples were kept on dry ice and
placed in pre-weighed and pre-cooled vials and were stored
at – 80 °C. Specimens were assayed in batches that were
freshly thawed. The neuropathological diagnoses were ob-
tained using the brain sampling and staining protocols of
the NNTC (Morgello et al. 2001). The diagnosis of HIV
encephalitis (HIVE) was made according to established
criteria (Budka 1991; Gelman et al. 2013).
Quantitative Real-Time PCR
About 100 mg of brain tissue was homogenized in 1 ml of
QIAzol reagent (RNeasy Mini Kit, Qiagen, Valencia, CA) for
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isolation of total RNA according to the standard manufac-
turer’s protocol. Single strand cDNA was prepared using
Bio-Rad iScript cDNA synthesis Kit (Bio-Rad, Hercules,
CA). 2 ug of brain mRNA were mixed with 8 ul of 5x
iScript reaction mix, 2 ul of iScript reverse transcriptase
and total volume was adjusted to 40 ul with nuclease-free
water. The reaction mixture was incubated in the Bio-Rad
I-cycler programmed for 5 min at 25 °C, 30 min at
42 °C, 5 min at 85 °C and held at 4 °C. For quantitation
of the mRNA primers and FAM probes were obtained for
GAD1 (Cat. No. Hs01065893_m1), GAD2 (Cat. No.
Hs00609534_m1), GJD2 (Cat. No. Hs00706940_s1),
ISG15 (Cat. No. Hs00192713_m1), MX1 (Cat.No.
HS00182073_m1), IRF1 (Cat.No. Hs00971959_m1),
GZMB (Cat.No. Hs01554355_m1), CD4 (Cat.No.
Hs01058407_m1), CD8A (Cat.No. Hs01555600_m1),
CD19 (Cat.No. Hs99999192_m1), CD68 (Cat.No.
Hs00154355_m1), CD163 (Cat.No. Hs01016661_m1),
VWF (Cat.No. Hs00169795_m1), PECAM1 (Cat.No.
Hs00169777_m1), from Applied Biosystems, Foster City,
CA, USA), Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH, Cat. No. Hs99999905_m1) was used as the
normalizing gene. For a 20 ul reaction mixture 1ul of
cDNA was mixed with 10 ul of TaqMan 2x PCR
Master Mix (Applied Biosystems), 8 ul H2O and 1 ul
ABI 20x primer (gene of interest or GAPDH). PCR reac-
tions were performed on Mastercycler RealPlex
(Eppendorf, Germany) under the following conditions: ac-
tivation (10 min at 95 °C), and 40 cycles of denaturation
(15 s at 95 °C) – annealing/extension (60 s at 60 °C).
Experiments were performed on 96-well plates, each sam-
ple was run in duplicates, triple negative controls and
standard calibrators were run on each plate. Duplicate CT
values were analyzed using the comparative CT (ΔΔCT)
method as described by the manufacturer (Applied
Biosystems). The amount of targets (2-ΔΔCT) was obtained
by normalizing to endogenous reference (GAPDH).
Immunoblotting
Frozen tissue samples were homogenized in 3x volume
of buffer (10 mM Tris–HCl, 5 mM MgCl2, 0.5 mM
dithiothreitol (DTT), 0.03 % Triton X-100, pH 7.8) by
silica beads beating (2 times for 20 s) and sonication (2
times for 20 s) with tubes kept on ice for 5 min be-
tween sessions. Protein concentration was determined
using Bio-Rad Protein Assay (Bio-Rad Laboratories,
Hercules, CA) and bovine serum albumin (BSA) stan-
dards. 15 ug of total protein were loaded into Criterion
Precast 18-well 4–20 % gradient Tris–HCl gel (Bio-Rad
Laboratories, Hercules, CA) for SDS-PAGE electropho-
resis and run at 180 volts for 45 min. Separated pro-
teins were transferred to PVDF membrane (Amersham
Biosciences, Piscataway, NJ) in 10 mM Tris-glycine
buffer containing 10 % methanol at 75 W for 1 h at
4 °C. The membrane was blocked in 5 % non-fat milk
in Tris buffer Saline (TBS-T; 50 mM Tris–HCl,
150 mM NaCl, 0.01 % Tween-20) for 1 h and incubat-
ed with mouse anti-GAD67 (Cat. No. ab22050, Abcam)
or mouse anti-GAPDH (Cat.No. sc-47724, Santa Cruz
Biotechnologies, Santa Cruz, CA, USA) primary anti-
bodies diluted in blocking solution overnight at 4 °C.
The membrane was washed three times in TBS-T and
incubated with sheep anti-mouse IgG antibodies (Cat.
No. Na931V, GE Healthcare, UK) diluted 1:1000 in
blocking solution for 2 h. Then the membrane was in-
cubated with Enhanced Chemiluminescence Detection
Reagent (Amersham Biosciences, Piscataway, NJ) for
2 min and exposed to Kodak BioMax XAR film
(Kodak, Rochester, NY). Film was developed and
scanned and bands densities were measured using
ImageJ software (NIH, Bethesda, MD, USA).
Immunohistochemistry
After formalin fixation, blocks of brain tissue were
trimmed and embedded in paraffin wax. Sections of tissue
(6–8 um) were mounted on glass slides (Superfrost Plus
Gold, Erie Scientific, Portsmouth, NJ). The sections were
deparaffinized in xylene, rehydrated in graded alcohols
and immersed in 0.01 M sodium citrate buffer heated in
a microwave oven for 20 min. Unspecific binding was
blocked for 20 min with 1 % normal serum and then
the sections were incubated overnight at 4 °C with prima-
ry antibodies diluted in blocking solution. Following pri-
mary antibodies were used: anti-GAD67 (Cat. No.
ab26116, Abcam, Cambridge Science Park, Cambridge,
England) diluted 1:1000, anti-CD31 (Cat. No. M0823,
Dako, Via Real, Carpinteria, CA, USA) diluted 1:30,
anti-granzyme B (Cat.No. GB-7, Sanquin, Sanquin Blood
Supply, Amsterdam, Netherlands) diluted 1:50, anti-CD8A
(Cat.No. M710301-2, Dako) diluted 1:50, anti-CD68
(Cat.No. M0814, Dako) diluted 1:50. Next day tissue
was treated with 3 % hydrogen peroxide for 10 min and
rinsed with TBS-T (50 mM Tris–HCl, 150 mM NaCl,
0.05 % Tween-20). Appropriate anti-mouse or anti-rabbit
Vectastain secondary antibodies were applied for 1 h,
followed by Vectastain ABC and Vectastain DAB color
development using peroxidase-diaminobenzidine reactions
(Vector Laboratories, Burlingame, CA). Sections were
dehydrated and mounted using Permount (Fisher
Scientific, Hampton, NH). Composite microscopic fields
were acquired by combining contiguous images taken
using an Olympus DP71 camera and Olympus DP
controller software (Olympus America Inc, Center Valley,
PA, USA).
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Immunofluorescence
Sections for immunofluorescence underwent deparaffinization
and antigen retrieval treatment as described above. After anti-
gen retrieval, tissue was permeabilized for 15 min with 0.1 %
Triton-X in Phosphate buffer saline (PBS) and treated with
ImageT FX signal enhancer (Invitrogen Molecular Probes,
Eugene, Oregon) for 30 min. Unspecific binding was blocked
for 1 h with 1 % normal serum and then the sections were
incubated overnight at 4 °C with primary antibodies diluted
in blocking solution. Primary antibodies were used: mouse
anti-GAD67 (Cat. No. mab5406, EMD Millipore
Corporation, Billerica, MA, USA) diluted 1:100, rabbit anti-
parvalbumin (Cat. No. ab11427, Abcam) diluted 1:1000,
mouse anti-dopamine receptor 2 (Cat.No. sc-5303, Santa
Cruz Biotechnologies, Santa Cruz, CA, USA) diluted 1:50.
Next day sections were rinsed in with TBS-T (50 mM Tris–
HCl, 150 mM NaCl, 0.05 % Tween-20) and mixture of sec-
ondary antibodies diluted 1:500 in PBS were applied for 3 hs
(AlexaFluor 488 goat anti-mouse (Cat.No. A11029), and
AlexaFluor 594 goat anti-rabbit (Cat.No.A11037), Life
Technologies, Grand Island, NY, USA). After incubation with
secondary antibodies, sections were rinsed with TBS-T and
treated with Sudan Black B (0.5 in 70 % ethanol) for 20 min.
Then sections were rinsed in ddH2O, air dried and mounted
using ProLong Gold with DAPI mounting media (Life
Technologies). Confocal images were then acquired with a
Zeiss LSM-510 Meta confocal microscope with 63x / 1.40
Oil DIC (WD=0.19 mm) objective (Carl Zeiss Microscopy,
Peabody, MA, USA) and processed using LSM Image
Browser (Zeiss).
Statistical Analysis
Statistical analysis was performed using Microsoft Excel
2010 (Microsoft Corporation, Redmond, Washington, DC,
USA), and GraphPad 6 (GraphPad Software, Inc., La Jolla,
CA, USA). Two-tailed Student’s t-test was used to compare
two groups. One-way analysis of variance with post hoc
Scheffé’s or uncorrected Fisher’s LSD tests were used to
compare the mean of one group to the mean of other groups.
Pearson’s correlation was used to analyze correlations be-
tween GABAergic mRNAs level and neurovirological,
neuroimmunological and neurocognitive measurements.
These data were log10 transformed to normalize the distribu-
tions. Significance of correlation was corrected for the false
discovery rate using the Bonferroni correction. Significance
was set at α=0.05. Fisher z-transformation was used to
estimate the significance of the difference between two cor-
relation coefficients found in two independent samples.
Multiple regression models were used to determine whether
potentially confounding factors such as age, gender, race,
and drugs of abuse affected GABAergic mRNA.
Results
GAD1, GAD2 and GJD2 mRNA Expression
Three markers of GABAergic interneurons in the DLPFC
were abnormally expressed in the HIV-infected patients com-
pared to normal uninfected controls. mRNAs that correspond
to GAD67, GAD65, and connexin 36 proteins all were
significantly lower in the HIV positive subjects versus
the HIV negative controls (for GAD1, -26 % and
p<10−4, for GAD2, -22 % and p<0.001, for GJD2, -
21 % and p=0.0043; Fig. 1a–c). When HIV-infected sub-
jects were divided into those that died before the era of
cART versus after, all three mRNAs were significantly
lower in both eras (by 30 and 24 % for GAD1, 19 and
24 % for GAD2, 17 and 22 % for GJD2; Fig. 1d–f).
Between group analysis using one-way analysis of vari-
ance (ANOVA) and post hoc Scheffé’s test yielded
F = 13.27 and p < 10−4 for GAD1 , F = 5.957 and
p= 0.0028 for GAD2, and F= 4.425 and p= 0.012 for
GJD2. The pre- and post-cART era groups did not differ
significantly from each other. When HIV-positive subjects
were sorted according to whether or not they had HIV
encephalitis (HIVE) at autopsy, the mRNAs were signifi-
cantly lower than HIV-negatives in the patients without
and with HIVE both (by 26 and 23 % for GAD1, 21
and 27 % for GAD2, 20 and 24 % for GJD2; Fig.1g–i).
Between group analysis using one-way analysis of vari-
ance (ANOVA) and post hoc Scheffé’s test yielded
F = 12.55 and p < 10−4 for GAD1 , F = 5.960 and
p = 0.0028 for GAD2 and F = 4.313 and p = 0.014 for
GJD2. The groups with and without HIVE did not differ
from each other significantly with respect to these
mRNAs.
Regional Distribution of the GABAergic Anomaly
in the CNS
To determine if specific brain regions were selectively
vulnerable to having low GABAergic markers, we mea-
sured GAD1 mRNA in a total of 16 sectors of the
human CNS, including 7 neocortical regions, 6 subcor-
tical regions, cerebellum and spinal cord (Fig. 2). Six
HIV negative controls and 6 HIV-infected subjects were
selected for study based upon their GABAergic mRNA
values in the DLPFC. There was substantial variation in
GAD1 mRNA expression between brain regions (F (16,
218) = 7.17, p< 10−4, two-way ANOVA). In almost all
regions GAD1 mRNA was lower in the HIV infected
subjects, including neocortex, neostriatum and cerebellar
lobule. Exceptions were spinal cord, paleostriatum
(globus pallidus) and hippocampus in which the lower
GAD1 expression was not statistically significant.
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Relationship of GABAergic mRNAs to Demographic
Factors and Substance use History
Some studies have suggested that substance abuse can pro-
duce changes in GABAergic transmission (Zhang et al. 2006;
Satta et al. 2008). When sorted according to self-reported his-
tory of drug abuse, HIV-infected subjects with and without
drug abuse history contained significantly lower values for
all three GABAergic markers mRNAs compared to controls
(by 25 and 28 % for GAD1, 24 and 27 % for GAD2, 25 and
27 % for GJD2; Fig. S1 a–c) . Between group analysis using
one-way ANOVA yielded F=9.242 and p<10−4 for GAD1,
F = 7.124 and p = 0.001 for GAD2, and F = 8.12 and
p=0.0004 for GJD2. Between-group comparisons revealed
no difference between subjects with and without a history of
drug abuse.
Several CNS conditions can influence the expression of
the above transcripts. To examine whether such confounders
impact the concentration of GABAergic mRNAs, HIV-
positive subjects were sorted according to whether or not they
had comorbid CNS disease (such as progressive multifocal
leukoencephalopathy (PML), primary CNS Lymphoma
(PCNSL), CMV ventriculoencephalitis (CMVE), toxoplas-
mosis Encephalitis (TE), meningitis (such as aseptic
leptomeningitis, bacterial leptomeningitis, cryptococcal
meningitis), or hemorrhages). All three mRNAs were sig-
nificantly lower in both groups (without and with comor-
bidities) of HIV-positives (by 25 and 28 % for GAD1, 22
and 29 % for GAD2, 23 and 22 % for GJD2; Fig. S3 g - i).
Between group analysis using one-way analysis of vari-
ance (ANOVA) and post hoc Tukey’s test yielded
F = 12.34 and p < 10−4 for GAD1 , F = 8.418 and
p = 0.0003 for GAD2 and F = 9.648 and p < 10−4 for
GJD2. The groups without and with comorbid CNS dis-
eases tissue did not differ from each other significantly
with respect to these mRNAs.
Age, gender and ethnicity are other potential vari-
ables that could affect GABAergic genes expression in
human brain specimens (Pinto et al. 2010; Seney et al.
2013). Multiple regression models showed that poten-
tially confounding co-variables including drug abuse,
age, gender, and race were not significantly related to
GAD1 and GJD2 mRNAs (not shown). For GAD2
mRNA statistical models suggested a significantly
higher level in males (p = 0.0027), but overall results
for GAD2 were not changed when the results were
corrected statistically for the influence of gender (data
not shown).
Fig. 1 Glutamate decarboxylase 1 (GAD1), glutamate decarboxylase 2
(GAD2), and connexin 36 (GJD2) mRNAs in the dorsolateral prefrontal
cortex of 449 HIV infected and 66 HIV seronegative patients (Panels a -
l). BRel. exp.^ on the ordinates denotes mRNA expression relative to
GAPDH mRNA. The number of subjects in each group is given in the
bars. Panels a - c. GABAergic mRNA expression was significantly lower
in the HIV infected patients. Panels d – f. HIV-positive subjects were
divided into subjects who died before and after the introduction of
cART. mRNA expression was significantly lower in pre-cART and
post-cART HIV patients as compared to the uninfected comparison
group. There were no significant differences between pre-cART and
post-cART groups. Panels g - i. HIV-positive subjects were divided ac-
cording to neuropathological diagnosis of HIV-encephalitis (HIVE). All
three mRNAs were significantly lower in patients without HIVE and with
HIVE when compared to the uninfected comparison group. There were
no significant differences between HIVE and no HIVE groups. Panels j -
l. HIV-positive subjects were divided according to the diagnosis of HIV-
associated neurocognitive disorders (HAND). Compared to the uninfect-
ed comparison group, all three mRNAs were significantly lower in pa-
tients without HAND and with HAND. There were no significant differ-
ences between HAND and no HAND groups. Mean± standard deviation.
*p< 0.05; **p < 0.01; ***p < 0.001
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Relationship Between GABAergic mRNAs, Clinical
Virology and Neurovirology
Correlation coefficients between brain HIV RNA loads and
GABAergic mRNAs in the DLPFC were not significant
(Table S2). When GABAergic mRNAs were correlated with
HIV RNA in blood plasma, the correlation coefficient was
negative and statistically significant for GAD2 mRNA
(n=264, r = - 0.1372, p=0.0258), but not the other mRNAs.
When GABAergic mRNAs were correlated with HIV RNA in
the CSF samples that were available, correlation coefficients
were negative and significant for two GABAergic mRNAs
(GAD2: n=191, r = -0.1582, p=0.0286; GJD2: n=191, r = -
0.1801, p=0.0127). Neurovirological correlations in patients
with HIVE often differ from those without HIVE (Gelman et
al. 2012a, 2013). To determine whether HIVE influenced the
neurovirological correlation with GABAergic mRNAs, pa-
tients with and without HIVE were evaluated separately.
GAD1 mRNA was negatively and significantly correlated
with brain HIV RNA in the subjects without HIVE, whereas
the correlation for patients with HIVE had a positive coeffi-
cient that almost reached significance (Table S2). Fisher r to Z
transformation showed that the two oppositely sloped regres-
sion lines were statistically different, comparing patients with
HIVE versus without it (two-tailed p=0.0278). These results
suggest that HIVE, which produces high loads of replicating
HIV in the brain and increased inflammation, tends to blunt
the decrease of the GABAergic mRNAs in HIV infected
patients.
When HIV-infected subjects were divided into those that
have low versus high viral load in the cerebrospinal fluid
(CSF), all three mRNAs were significantly lower in both
groups of HIV-positives (by 22 and 36 % for GAD1, 19 and
36 % for GAD2, 22 and 36 % for GJD2; Fig. S3 a - c).
Between group analysis using one-way analysis of variance
(ANOVA) and post hoc Tukey’s test yielded F=12.44 and
p<10−4 for GAD1, F = 10.33 and p<10−4 for GAD2, and
F=14.37 and p<10−4 for GJD2. The low and high viral load
in the CSF groups did not differ significantly from each other.
When HIV-positive subjects were sorted according to low
versus high viral load in the frontocortical grey matter, all
three mRNAs were significantly lower in both groups of
HIV-positives (by 27 and 25 % for GAD1, 20 and 23 % for
GAD2, 22 and 24 % for GJD2; Fig. S3 d - f). Between group
analysis using one-way analysis of variance (ANOVA) and
post hoc Tukey’s test yielded F = 12.29 and p < 10−4 for
GAD1, F = 5.673 and p= 0.0037 for GAD2 and F = 9.642
and p<10−4 for GJD2. The groups with low versus high viral
load in brain tissue did not differ from each other significantly
with respect to these mRNAs.
Relationship of GABAergic mRNAs to Neurocognitive
Impairment
Abnormal GABAergic transmission occurs in diseases that
can adversely affect neurocognitive test performance, espe-
cially on tasks that are driven by the DLPFC (Volk et al.
2000; Woods et al. 2009). To address whether the GABA
disturbance was related to HIV-associated neurocognitive dis-
orders (HAND), we sorted the subjects according to the diag-
nosis of HAND and the GABAergic mRNAs were compared
in the two groups. All three GABAergic mRNAs were signif-
icantly lower in the subjects with HAND relative to the unin-
fected controls; the same result was obtained in the subjects
without HAND (Fig. 1j–l). Between group analysis using one-
way analysis of variance (ANOVA) and Scheffé’s post hoc
test yielded F=8.420 and p=0.0003 for GAD1, F = 7.384
and p< 0.0008 for GAD2, and F= 10.51 and p< 10−4 for
GJD2. There were no significant differences between
HAND and no HAND groups. When subjects with HAND
were sorted according to the severity of impairment, all three
mRNAs were significantly lower in patients diagnosed with
HIV-associated dementia (HAD) and Mild Neurocognitive
Disorder (MND) compared to seronegative controls (by 24
and 18 % for GAD1, 32 and 22 % for GAD2, 29 and 22 %
Fig. 2 Glutamate decarboxylase 1 mRNA (GAD1) expression was
measured in 16 different brain regions obtained from 6 HIV-infected
patients and 6 uninfected patients. Using two-way ANOVA, only varia-
tion in GAD1 mRNA concentrations between brain regions was signifi-
cant (F (16, 218) = 7.17, p < 10−4). GAD1 was lower in the HIV infected
brain specimens in most regions including neocortex, cerebellum and
neostriatum (caudate nucleus and putamen). Uncorrected Fisher’s LSD
tests were significant for dorsolateral prefrontal (- 51.7 %, p = 0.010),
anterior cingulate (- 51.2 %, p = 0.009), superior temporal (- 44.5 %,
p = 0.013), somatosensory (- 55.6 %, p= 0.042), and visual cortices (-
45.4 %, p= 0.038), cerebellar lobule VIIa (- 51.5 %, p = 0.003), head of
caudate nucleus (- 42.5 %, p= 0.009), putamen (- 40.1 %, p= 0.049), and
amygdala (- 60 %, p= 0.012). Mean decrease of GAD1 mRNA expres-
sion in the orbitofrontal cortex was - 36.2 % and almost reached signif-
icance (p = 0.0728). Spinal cord, paleostriatum, and hippocampus also
had slightly lower GAD1 in the HIV infected brain specimens, but those
differences were not significant statistically. Relative expression ofGAD1
mRNA was normalized to GAPDH mRNA. Mean ± standard deviation.
*p< 0.05; **p < 0.01; ***p < 0.001
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for GJD2; Fig. S1 d–f). One-way analysis of variance
(ANOVA) yielded F = 5.294 and p = 0.0015 for GAD1,
F = 6.688 and p = 0.0002 for GAD2, and F = 7.215 and
p=0.0001 for GJD2. Groups of HIV-positives with different
degrees of cognitive impairment did not differ from each oth-
er. There were no significant differences between HIV-
patients diagnosed with Asymptomatic Neurocognitive
Impairment (ANI) and controls.
Using the composite neurocognitive impairment T score,
Pearson’s correlation analysis showed no significant correlation
with GABAergic mRNAs in the DLPFC. When GABAergic
mRNAs were compared to performance in distinct functional
domains that were assessed in the test battery, there was a sig-
nificant correlation between lowGABAergicmRNAs andworse
performance on the verbal fluency task (p=0.0036 for GAD1
mRNA, p=0.0005 for GAD2 mRNA, p=0.0013 for GJD2
mRNA) after correction for multiple comparisons (Table 1).
Relationships Between GABAergic mRNAs, Endothelial
and Immune Cell Markers
In addition to the potential influence of CNS virus replication,
it has been suggested that neuroimmune anomalies including
changes in the neurovascular unit (Strazza et al. 2011) and
heightened interferon responses could drive HAND (Gelman
et al. 2012a). When mRNAs that mark neurovascular and
neuroimmune type changes were examined, strong correla-
tions were found between low GABAergic mRNAs and high
expression of the endothelial cell markers PECAM1 and VWF
(Table 2). Low GABAergic mRNAs were correlated signifi-
cantly, but less strongly with high expression of neuroimmune
type markers including a prototypical type 1 interferon re-
sponse gene (MX1), a type 2 interferon response gene
(IRF1), macrophages (CD163 and CD68), CD8+ cytotoxic
T lymphocytes (CD8A), and natural killer cells (GZMB). In
contrast, markers for B lymphocytes (CD19) and CD4+ T
lymphocytes (CD4) were not significantly correlated with
low GABAergic mRNAs. Immunohistochemical staining of
brain tissue for marker antigens corresponding to endothelial
cells, macrophages, CD8+ lymphocytes, and natural killer
cells generally confirmed these associations at protein and
cellular levels (Fig. 3).
Interrelationships Between GABAergic, Dopaminergic
and Enkephalinergic mRNAs
Dopaminergic and enkephalinergic neural transmission both
have been shown to be neurochemically abnormal in the
DLPFC of this HIV infected autopsy cohort (Gelman et al.
2012b). These neurotransmitter type changes were compared to
the results for GABAergic mRNAs (Fig. S2). In seronegative
controlsGAD1mRNAwas positively and significantly correlated
with the transcript of a key dopaminergic receptor (DRD2L) that
was previously shown to be regulated in the DLPFC of HIV
infected patients (n=66, r=0.267, p=0.03). In contrast, the same
correlation analysis in the HIV infected subjects produced a sig-
nificant negative correlation coefficient (n=449, r = - 0.157,
p=0.0008). Using bootstrapping and Fisher z-transformations
these correlations were significantly different from each other
(two-tailed p=0.011). Thus, reduced expression of GABAergic
markers is significantly related to higher DRD2L expression in
the HIV infected subjects but not in seronegative controls. When
HIV-positive subjects were grouped according to the clinical
diagnosis of HAND versus no HAND there was a significant
correlation between GABAergic mRNAs and DRD2L in the
subjects with HAND (n=197, r= - 0.183, p=0.01). Infected
subjects without HAND also exhibited a negatively sloped re-
gression line, but the correlation was not significant statistically
(n=43, r= - 0.159, p=0.306), probably due to the more limited
number of available subjects in that subgroup.
Table 1 GABAergic transcripts correlated with normalized neurocognitive T-scores
HIV+ GAD1 mRNA GAD2 mRNA GJD2 mRNA
Neurocognitive test domain n r p r p r p
Memory 218 0.0322 0.6363 0.0256 0.7070 0.0528 0.438
Attention and working memory 212 0.0229 0.7403 0.0791 0.2515 0.0493 0.475
Learning 219 0.0073 0.9145 0.0653 0.3361 0.0539 0.4274
Motor 202 0.0353 0.6180 0.0306 0.6650 0.1124 0.1112
Verbal fluency 216 0.1974 0.0036* 0.2358 0.0005* 0.2171 0.0013*
Abstract executive 209 0.0614 0.3771 0.0974 0.1606 0.0918 0.1861
Speed of information processing 217 0.0377 0.5810 0.0375 0.5827 0.0461 0.4993
Global T-Score 196 0.0793 0.2690 0.1003 0.1619 0.1072 0.135
*Asterisk denotes statistically significant p value. GABAergic transcripts were measured in the frontal neocortex
HIV human immunodeficiency virus type 1, HIVE HIV encephalitis, r correlation coefficient
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Preproenkephalin mRNA (PENK) was shown previously
to be lower in HIV infected subjects in this patient cohort
(Gelman et al. 2012b). Lower PENK was correlated signifi-
cantly with low GABAergic expression in HIV infected pa-
tients (Table 2).
GAD67 Protein Expression and Tissue Localization
Western blotting for GAD67 (the protein product of GAD1
transcript) showed that GAD67 expression was lower in 36
representative HIV infected subjects as compared to 12 unin-
fected subjects (Fig. 4). GAD67-immunostainining in the
DLPFC further illustrated that protein staining intensity was
lower in the neocortex of infected subjects (Fig. 5). Stain
intensity in DLPFC was lowered diffusely in cell bodies and
neural processes of the cortical laminae. Dual staining was
performed to determine whether GAD67 and higher DRD2
protein expression were co-localized in the same neurons.
Weak GAD67 staining hindered the effort to localize the two
antigens in the infected subjects (not illustrated). When we
stained for GABAergic cell markers that were more abundant-
ly expressed, inhibitory interneurons in DLPFC often had
strong expression of DRD2 in the HIV infected, but not in
the seronegative control specimens (Fig. 6b). Dual staining
Table 2 GABAergic transcripts correlated with neuroimmunological and endothelial markers
HIV+ (n= 449) GAD1 mRNA GAD2 mRNA GJD2 mRNA
r p r p r p
MX1 mRNA −0.1375 0.0035* −0.1721 0.0002* −0.0465 0.3256
ISG15 mRNA −0.0306 0.5178 −0.0510 0.2809 −0.0186 0.6943
IRF1 mRNA −0.1574 0.0008* −0.1504 0.0014* −0.0804 0.0888
CD68 mRNA −0.1946 0.0000* −0.1732 0.0002* −0.1181 0.0123*
CD163 mRNA −0.1950 0.0000* −0.1081 0.0221* −0.0750 0.0563
CD8A mRNA −0.1197 0.0112* −0.1821 0.0001* −0.0369 0.4354
CD4 mRNA −0.0808 0.3426 −0.0647 0.4476 0.0854 0.3157
CD19 mRNA −0.0501 0.2895 −0.0661 0.1620 −0.0173 0.7145
GZMB mRNA −0.1450 0.0021* −0.1553 0.0010* −0.1018 0.0310*
VWF mRNA −0.2769 0.0000* −0.2902 0.0000* −0.0501 0.2895
PECAM1 mRNA −0.3419 0.0000* −0.3529 0.0000* −0.1980 0.0000*
PENK mRNA 0.2968 0.0000* 0.3534 0.0000* 0.2018 0.0000*
*Asterisk denotes statistically significant p value. GABAergic, neuroimmunological and endothelial transcripts were measured in the frontal neocortex
HIV human immunodeficiency virus type 1, r correlation coefficient
Fig. 3 Neuroimmune and endothelial cells were immunostained in the
dorsolateral prefrontal cortex of the HIV-seronegative control (panels a, c,
e, g) and HIV-infected subjects (b, d, f, h). CD8+ cytotoxic T cells
(arrows, a vs b) and CD68+ macrophages (arrows, c vs d) were more
numerous in specimens from HIV-infected subjects with low GAD1 ex-
pression, as suggested by concentrations of the corresponding mRNAs
(see Table 2). Granzyme B-containing inflammatory cells were more
numerous in specimens from HIV- infected subjects with low GAD1
expression (arrows, e vs f). Staining for the endothelial cell marker
CD31 produced more intense marking of blood vessel walls (arrows) in
HIV- infected subjects with lowGAD1 (g vs h). Bars represent 50 um in a
– f, and 20 um in g and h
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for combinations of two different markers of inhibitory neu-
ronal subpopulations confirmed that the loss of neocortical
GAD67 staining occurred in viable interneurons. Examples
are illustrated in Fig. 6a, which shows the lack of staining
for GAD67 in numerous PV-stained inhibitory neurons of
the HIV infected patients. In contrast, the seronegative con-
trols had primarily PV-stained neurons that were positively
stained for GAD67. The lack of GAD67 staining in the HIV
infected patients was observed almost exclusively in interneu-
rons with morphologically typical-appearing nuclear and peri-
karyal features.
Discussion
This study elucidates the neurochemical, neuropathological,
neurocognitive and neurovirological aspects of abnormally
low expression of GABAergic markers in HIV-infected pa-
tients. Approaching these questions using tissues from a large
number of patients imparted strong statistical power. Results
with three separate GABAergic mRNAs were consistent,
which provided added rigor to the experimental design. Our
emphasis on the DLPFC was appropriate given that HAND
and other diseases with abnormal GABAergic transmission
Fig. 4 Glutamate decarboxylase 67 (GAD67) protein and mRNA expres-
sion in the dorsolateral prefrontal cortex. GAD67 immunoblotting was
done on 36 HIV-infected subjects and 12 seronegative controls. GAPDH
blots were done for loading controls. Equal amounts of protein were loaded
to each well. GAD67 band intensities were significantly lower in 36 HIV+
subjects compared to 12 HIV- subjects (-51.2 %, p=0.0001, panel c). Band
intensities for ten representative subjects are illustrated in panel a. GAD1
mRNA expression is shown for comparison (b), mean GAD1 mRNA de-
crease is -39,8 %, (p = 0.001). GAD67 is expressed as relative to the
GAPDH band intensity. GAD1 is expressed as relative to GAPDH
mRNA. Mean± standard deviation is shown. P values were obtained using
the Student’s t test. *p<0.05; **p<0.01; ***p<0.001
Fig. 5 Glutamate decarboxylase 67 (GAD67) immunoreactivity in brain
tissue from an HIV infected patient (b, d, f, h) and a seronegative control
(a, c, e, g). Panels a and b illustrate dorsolateral prefrontal cortex
(DLPFC) with neocortical laminae labeled I through VI at left. The spec-
imen from the HIV infected subject (b) contains less intense staining in all
of the laminae compared to the seronegative patient (a). Boxed areas in a
and b are magnified in c and d and illustrate less intense immunostaining
in pyramidal cell cytoplasm, in pear-shaped interneurons and in neuritic
processes. In the neostriatum (caudate nucleus), decreased GAD67 im-
munostaining in the HIV infected subject was not as clear-cut but still was
present (e vs f). The neurons in the globus pallidus also were stained less
intensely in the HIV infected subject. Note that the number of stained
neurons in the HIV infected subject is similar to the seronegative control
(g vs h). Scale bars are 200 um in a and b, and 100 um in c – f
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have neuropsychological deficits that can be traced to abnor-
mal output of the DLPFC (Iudicello et al. 2007; Woods et al.
2009). GABAergic neurotransmission is abnormal in many
HIV-infected patients, as previously suggested (Masliah et
al. 1995; Fox et al. 1997; Gelman et al. 2012a). Our data on
brain virus replication show that the GABAergic anomaly is
not correlated with the amount of replicating HIV-1 in the
CNS. Further, the data show no significant association with
HIVE, which is a neuropathology driven by replicating HIV-1
in the CNS. Also, the anomaly was not normalized in patients
taking cART, which is a treatment that lowers viral replication.
All of these observations indicate that reduced expression of
GABAergic markers is not driven directly by the amount of
replicating HIV-1 in the CNS or systemically. The lack of
linkage with replicating HIV-1 as demonstrated herein is strik-
ing because it runs contrary to many conclusions suggested by
prior work done using far fewer subjects (Masliah et al. 1995).
Our conclusion regarding the lack of a direct role of HIV-1,
while potentially counterintuitive and at-odds with prior sug-
gestions draws support from the large patient sample. Our
conclusion also is consistent with recent data showing that
the neurovirological correlation between brain viral replica-
tion and HAND is not significant in most patients taking
cART (Gelman et al. 2013).
Neuroimmune Responses were Related to Abnormal
Expression of GABAergic Markers
This and other studies show that several aspects pertaining to
the neurobiology of HIV infection in humans do not appear to
be controlled directly by HIV replication in the CNS (Gelman
et al. 2012a; Gelman et al. 2013). Indeed, there is abundant
evidence that host immune responses in the CNS may play a
critical role in driving HAND in a manner that is partly inde-
pendent of HIVreplication (Glass et al. 1995). Consistent with
that, we found that low GABAergic transcripts were signifi-
cantly correlated with higher neuroimmune type markers in
the brain including interferon response genes. These findings
agree with reports which showed that the host immune re-
sponse in the CNS (e.g., activation of brain macrophages
and microglia), but not the concentration of HIV RNA per
se, drove the development and progression of neurocognitive
impairment (Glass et al. 1995; McArthur et al. 2010; Gelman
et al. 2013). The fact that patients without encephalitis often
had abnormal GABAergic transmission remains unexplained,
yet is consistent with the fact that HAND also is highly prev-
alent in patients without encephalitis.
Substance use History was not Related to Abnormal
GABAergic Markers Expression
Drug addiction was common in this HIV-infected patient co-
hort and could have influenced synaptic transmission; 89 out
of 204 HIV-infected patients with self-reports had current or
past history of substance abuse. That rate is comparable gen-
erally to other HIV-infected populations in which lifetime
prevalence of any substance use ranges from 23 to 56 %
(Klinkenberg et al. 2004). In our cohort GABAergic expres-
sion was low in subjects with and without a history of drug
dependence, and the two groups of subjects were not statisti-
cally different from each other. This result was somewhat
unexpected because substance abuse often does result in the
altered GABAergic neurotransmission. Altered expression of
GABAergic mRNAs and proteins were reported for cocaine
(Enoch et al. 2012), nicotine (Satta et al. 2008), methamphet-
amine (Zhang et al. 2006; Anneken et al. 2013), and morphine
use (Sultana et al. 2010). These discrepancies are likely to be
related to differences in experimental designs, as studies of
substance abuse predominantly utilized animal models and
Fig. 6 The six panels in a illustrate that loss of GAD67 staining in HIV
infected patients does not correspond to the dropping out of interneurons.
Immunofluorescence for interneuronal markers GAD67 and parvalbumin
(PV) show that the cortical interneuron from the HIV-infected subject
contains less intense GAD67 staining compared to the seronegative con-
trol. PV immunoreactivity of interneurons and neuritic processes is of
equivalent intensity in these two specimens. The six panels in b illustrate
that HIV-infected patients with HAND had high expression of dopamine
receptor 2 (DRD2) in cortical interneurons, when interneuron from a
seronegative patient lacks DRD2 staining. PV immunoreactivity of inter-
neurons and neuritic processes is of equivalent intensity in these two
specimens. Scale bars are 10 um
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acute dosing paradigms. The combined influence of substance
abuse and HIV-1 on inhibitory systemwas studied in very few
prior studies (Langford et al. 2003; Chana et al. 2006). It has
been hypothesized that calbindin- and parvalbumin-
expressing interneurons are selectively vulnerable to neurode-
generation in methamphetamine-using patients with HIVE.
We suggest that the reason for our sharply contrasting conclu-
sion (that these neurons do not undergo degeneration) is that
we used multiple markers of inhibitory neurons to illustrate
the lack of cell dropout. Other differences between this and
previous studies include their use of smaller cohorts with
highly restrictive inclusion and exclusion criteria, and the in-
herent differences between using postmortem human brain
tissue versus animal models.
The Neurovascular Unit is Linked to Abnormal
Expression of GABAergic Markers
Brain gene array data have suggested that patients with
HAND who are taking cART, but do not have high viral rep-
lication rates in the CNS or encephalitis, might harbor a dis-
turbance in the neurovascular unit (NVU) (Gelman et al.
2012a). The components of the NVU include endothelial
cells, astrocytic end feet, nerve endings and accessory cells
that include pericytes, perivascular microglial cells, and mac-
rophages (Ballabh et al. 2004). It is notable that the most
significant association of reduced expression of GABAergic
markers that we observed was with higher expression of the
brain endothelial cell markers. Since the endothelial cells are
in direct contact with blood plasma, our results suggest that
changes in GABAergic transmission may be linked via the
NVU to systemic changes in virally suppressed patients, such
as persistent inflammation (Gelman 2015). One possible sce-
nario is that increased expression of cell adhesion molecules
and endothelial markers (e.g., VCAM-1, ICAM-1, PECAM1,
and von Willebrand factor) facilitates the transmigration of
infected immune cells across the BBB (Eugenin et al. 2006).
Increased concentrations of inflammatory molecules and viral
proteins in the brain tissue often result in activated astroglia,
disrupted glutamate / glutamine cycle and lower rate of GADs
expression (Janda et al. 2011).
Loss of GABAergic Immunostaining Does not Reflect
Neurodegeneration
Studies conducted before the era of cART suggested that
HAND is a classical neurodegenerative disease that produces
the loss of nonviable inhibitory interneurons. The validity of
this suggestion as it pertains to cART-era brain specimens with
HAND remains doubtful (Gelman and Moore 2011; Gelman
2015). This concept also has been challenged in patients with
schizophrenia who have GABAergic disturbances (Benes
et al. 1991). Our observations indicate that loss of
GABAergic mRNAs and protein occurs in viable inhibitory
interneurons. DLPFC specimens from HIV-infected patients
generally had decreased GAD67 staining intensity across the
cortical lamina, and the affected interneurons still expressed
calretinin, parvalbumin or somatostatin, which are alternative
markers expressed by GABAergic neurons. The affected neu-
ronal profiles had the morphological characteristics of fully
viable interneurons with normally proportioned cell bodies
and nuclear profiles that were not suggestive of necrosis or
apoptosis. Our results offer little or no support for the hypoth-
esis that the abnormal GABAergic neural transmission in HIV
infected brain specimens is caused by classical neurodegener-
ation. The data suggest instead that transcription of genes is
down-regulated, or that the stability of mRNAs of rate limiting
enzymes is lost. Such changes lie within the range of changes
that can drive synaptic plasticity and accommodation to stress
(Gelman et al. 2012b). Our suggested interpretation is com-
patible with results from patients with schizophrenia, mood
disorders, and Parkinson’s disease, in whom neocortical
GAD1 mRNA is abnormally expressed and loss of inhibitory
neurons is not observed (Akbarian et al. 1995; Volk et al.
2000; Lanoue et al. 2010). Our results also agree with a report
showing that parvalbumin-expressing interneurons did not
drop out in the neocortex of patients with HIVE (Masliah et
al. 1992). Taken altogether, the GABAergic disturbance in
HIV infected patients probably reflects synaptic plasticity
and accommodation instead of classical neurodegeneration
of a subpopulation of cells.
Reduced Expression of GABAergic Markers is Linked
to Worse Cognitive Performance in HIV-1
Down-regulated levels of GAD1 mRNA and GAD67 protein
are characteristic features of various neurocognitive and psy-
chiatric disorders, including autism, bipolar disorder, epilepsy,
and schizophrenia (Akbarian et al. 1995; Volk et al. 2000;
Thompson et al. 2009). This study found that HIV-infected
patients with and without neurocognitive impairment both had
lower GABAergic mRNAs, but were not significantly differ-
ent when compared to each other. Moreover, we did not find
significant difference between GABAergic mRNAs concen-
trations in groups with various degrees of cognitive impair-
ment. Thus, abnormal GABAergic transmission per se is not a
promising candidate biomarker for the nosological diagnosis
of HAND. We did find, however, that all three GABAergic
mRNAs were correlated specifically with worse performance
on verbal fluency tasking, which also is abnormal in patients
with frontal lobe trauma, Parkinson’s disease, and
Huntington’s disease (Millikin et al. 2004). Verbal fluency
tasking has two distinct functional components – phonemic
(letter) and semantic (category) fluency, each consisting of
two subtasks – clustering and switching. More than 40 % of
cases of impaired verbal fluency in HIV-infected patients have
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been linked to switching impairment (Millikin et al. 2004).
Voxel-based lesion symptom mapping shows that phonemic
switching is driven by the frontal lobes, whereas semantic
switching relies on medial temporal lobes (Baldo et al.
2006). In HAND both semantic and phonemic fluency deficits
are of similar magnitude, which suggests that frontal and tem-
poral lobe functions both are involved. A key niche for future
study is whether abnormal GABAergic transmission in the
temporal lobes disproportionately impacts worse performance
on tests of semantic switching.
Abnormal Expression of GABAergic Markers
is Interrelated with Other Neurotransmitter Transmission
Systems
Using the same cohort of HIV infected patients, it was shown
previously that failure to suppress the expression of dopamine
receptor type 2 long isoform mRNA (DRD2L) in the DLPFC
was associated with worse neurocognitive performance
(Gelman et al. 2012b). The implied interpretation is that lower
expression of DRD2L is a beneficial accommodation driven
by higher presynaptic tone. The same report showed that
enkephalinergic neural transmission also undergoes an ac-
commodative type of decrease in many HIV infected brains.
Both of those changes illustrate that synaptic plasticity could
be central to the general mechanism of HAND. Abnormal
expression of GABAergic genes was linked to changes asso-
ciated with higher dopaminergic tone and lower
enkephalinergic synaptic tone. These neurotransmitter sys-
tems interactions often could be observed histologically in
tissue sections, as in our finding of higher expression of
DRD2 in the interneurons lacking GAD67 immunoreactivity.
These observations in HIV infected patients are consistent
with reports from uninfected people that DRD2 is mostly
expressed by large parvalbumin-expressing interneurons and
small pyramidal neurons (Khan et al. 1998).Mechanistic stud-
ies indicate that dopamine stimulation of DRD2 and overex-
pression of DRD2 decreases GABA synthesis in inhibitory
interneurons (Seamans et al. 2001). In turn, it is suggested that
the lower GABA inhibitory currents lead to a shift toward
excitation in local inhibitory microcircuits, which results in
uncontrolled spread of activation and a decreased signal-to-
noise ratio. At the behavioral level, the clinical manifestations
of inhibitory circuit dysfunction include impaired working
memory, planning and executive functions, slowed thinking,
and word finding difficulties. All these features are character-
istic neuropsychological findings in patients with schizophre-
nia and HAND (Seamans and Yang 2004; Iudicello et al.
2007; Woods et al. 2009). Thus, higher dopaminergic tone is
one potential mechanism that could diminish GABAergic
transmission in HIV-infected patients. While the differing
types of neurotransmitter systems exhibit substantial interre-
lationships to each other, they do not necessarily drive the
same functional deficit. For example, the GABAergic anom-
aly in DLPFC relates primarily to worse performance on tasks
of verbal fluency (Table 1, discussed above), whereas defec-
tive dopaminergic tone in the DLPFC (Gelman et al. 2012b)
was related to a broader spectrum of neurocognitive dysfunc-
tion (Seamans and Yang 2004). In contrast to those systems,
abnormal enkephalinergic transmission (low PENK mRNA)
showed little relationship to any of the neurocognitive func-
tions that were examined. A highly complex picture emerges
that involves shifting of multiple interconnected neurotrans-
mitter systems, each having implications regarding particular
aspects of abnormal neurocognitive function in HAND.
In sum, this neurochemical survey shows that GABAergic
markers are abnormally low in the frontal neocortex of a sub-
stantial proportion of HIV infected patients. The differences
were likely to have been regulated transcriptionally versus
being the results of pathological neurodegeneration. Worse
performance on tasks of verbal fluency was related signifi-
cantly to lower frontocortical GABAergic marker expression,
but other types of tasking were not related to it. Neither brain
HIV replication nor encephalitis were significantly associated
with GABAergic abnormalities. Brain markers associated
with activated neuroimmunity and heightened endothelial cell
activity both were linked significantly to low GABAergic
marker expression, which suggests involvement of systemic
immunity and the NVU.
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